1.1. Жукова Л.Г. Современные возможности и перспективы таргетной терапии при раке молочной железы. Практич. онкология. 2010; 11 (3): 182-91.2.2. Переводчикова Н.И. Современная тактика адъювантной лекарственной терапии больных операбельным (ранним) раком молочной железы. Соврем. онкология. 2007; 2: 12-8.3.3. Ряженов В.В., Горохова С.В. Анализ заболеваемости раком молочной железы с учетом генотипирования по HER2-статусу на территории РФ. Соврем. онкология. 2010; 3 (11): 19-22.4.4. Семиглазов В.Ф., Семиглазов В.В. Скрининг рака молочной железы. Практич. онкология. 2010; 11 (2): 60-5.5.5. Семиглазов В.Ф. и др. Неоадъювантная терапия рака молочной железы с повышенной экспрессией HER2. Фарматека. 2010; 14: 12-7.6.6. Состояние онкологической помощи населению России в 2011 году. Под ред. Чиссова В.И., Старинского В.В., Петровой Г.В.. М.: ФГБУ МНИОИ им. П.А. Герцена Минздрава России, 2012.7.7. Black D, Younger J, Martei Y et al. Recurrence risk in T1a-b, node-negative, HER2-positive breast cancer. Breast Cancer Res Treat 2006; 100 (l). Abstr. 2037.8.8. Chia S, Norris B, Speers C et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008; 26: 5697-6704.9.9. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.10.10. Gianni L, Dafni U, Gelber R et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 2011.11.11. Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1NoMo breast cancer: a nationwide population based study. Clin Cancer Res 2003; 9: 923-30.12.12. McArthur HL, Morris PG, Patil S et al. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer study rationale. Proc Breast Symp 2009. Abstr. 228.13.13. Perou CM. Therapeutic implication of the breast tumor intrinsic subtypes. The Breast 2007; 16 (Suppl. 1). Abstr. s2, s7.14.14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.15.15. Recht A, Come SE, Henderson IC et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334 (21): 1356-61.16.16. Romond EH, Perez КL, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.17.17. Ross JS, Fletcher JA, Linette GP et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncolog 2003; 8(4): 307-25.18.18. Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC≥T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC≥TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2/neu positive early breast cancer patients. Abstr. A-52. 29th Ann San Antonio Breast Cancer Sympos 2006.19.19. Tovey SM, Brown S, Doughty JC et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors. Br J Cancer 2009; 100: 680-3.20.20. Untch M, Gelber RD, Jackisch C et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19: 1090-6.21.21. Van'T Veer LJ, Dae H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.22.22. Viani GA, Afonao SL, Stefano EJ et al. Adjuvant trastuzumab in the treatment of HER2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.23.23. Winer EP, Piccart-Gebhart MJ et al. HeR2-positive breast cancer in current standards practice and future directions management of HER-positive breast cancer. ASCO 2006.